尿雌激素代谢物与前列腺癌风险：一项初步研究。
Urinary estrogen metabolites and prostate cancer risk: a pilot study.
机构信息
Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia 20057, USA.
出版信息
Prostate. 2011 Apr;71(5):507-16. doi: 10.1002/pros.21262. Epub 2010 Sep 30.
BACKGROUND
The high incidence of and few identified risk factors for prostate cancer underscore the need to further evaluate markers of prostate carcinogenesis. The aim of this pilot study was to evaluate urinary estrogen metabolites as a biomarker of prostate cancer risk.
METHODS
Using a liquid chromatography-tandem mass spectrometry method, urinary concentrations of 15 estrogen metabolites were determined in 77 prostate cancer cases, 77 healthy controls, and 37 subjects who had no evidence of prostate cancer after a prostate biopsy.
RESULTS
We observed an inverse association between the urinary 16-ketoestradiol (16-KE2) and 17-epiestriol (17-epiE3)--metabolites with high estrogenic activity--and prostate cancer risk. Men in the lowest quartile of 16-KE2, had a 4.6-fold risk of prostate cancer (OR=4.62, 95% CI=1.34-15.99), compared with those in the highest quartile.
CONCLUSIONS
We observed modest differences in estrogen metabolite concentrations between prostate cancer patients and subjects without cancer. Larger studies with both androgen and estrogen measurements are needed to confirm these results to clarify further whether estrogen metabolites are independent biomarkers for prostate cancer risk and whether androgen/estrogen imbalance influences prostate cancer risk.
背景
前列腺癌的高发率和少数已确定的风险因素突显了进一步评估前列腺癌发生标志物的必要性。本研究旨在评估尿雌激素代谢物作为前列腺癌风险的生物标志物。
方法
采用液相色谱-串联质谱法，检测 77 例前列腺癌病例、77 例健康对照和 37 例前列腺活检后无前列腺癌证据的受试者的 15 种尿雌激素代谢物浓度。
结果
我们观察到尿液中具有高雌激素活性的代谢物 16-酮雌二醇（16-KE2）和 17-表雌三醇（17-epiE3）与前列腺癌风险呈负相关。与最高四分位数相比，16-KE2 最低四分位数的男性患前列腺癌的风险增加 4.6 倍（OR=4.62，95%CI=1.34-15.99）。
结论
我们观察到前列腺癌患者和无癌症患者的雌激素代谢物浓度存在差异。需要进行更大规模的研究，同时测量雄激素和雌激素，以证实这些结果，进一步阐明雌激素代谢物是否是前列腺癌风险的独立生物标志物，以及雄激素/雌激素失衡是否影响前列腺癌风险。
Zotero 插件